Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
  • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4702—Regulators; Modulating activity
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y204/00—Glycosyltransferases (2.4)
  • C12Y204/02—Pentosyltransferases (2.4.2)
  • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
  • G01N2333/235—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Bordetella (G)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/90—Enzymes; Proenzymes
  • G01N2333/91—Transferases (2.)
  • G01N2333/91091—Glycosyltransferases (2.4)
  • G01N2333/91142—Pentosyltransferases (2.4.2)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
  • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Definitions

• the present invention relates to assay technologies for the detection of interactions between biomolecules. Particularly, the present invention relates to the identification of proteins interacting with the ADP-ribosylation in cancer-related pathways and viral infections.
• An aim of the present invention is to provide a robust assay technology suitable for high-throughput screening for a wide range of hydrolysing and non-hydrolysing ADP-ribose binders.
• ADP-ribosylation is a post-translational modification involved in the regulation of many diverse processes in the cell. Despite its physiological importance, the intricate interplay of ADP-ribose transfer, detection and removal are not well understood on the molecular level.
• the human genome encodes many different binders (“readers”) of ADP-ribosyl modified proteins as well as proteins that are able to hydrolyse and remove the ADP-ribosyl groups (“erasers”) (Teloni & Altmayer, 2016).
• Macrodomains represent one of the largest class of ADP-ribose binders known in humans. Many of them are encoded as part of other multidomain proteins such ADP-ribosyl-transferases (PARP9, PARP14, PARP15) or histones (macroH2A variants).
• Other macrodomains such as MDOl, MD02, PARG or TARG1 possess hydrolysis activity and are integral actors in ADP-ribose signalling pathways.
• PBZ PAR-binding zinc finger
• WBM PAR binding motif
• Macrodomains of pathogenic viruses represent another class of ADP-ribose binders.
• Viruses such as coronaviruses or togaviruses are known to harbour macrodomains that can remove ADP-ribose from proteins inside the host cell. These viral macrodomains are implied to weaken the host virus defence mechanism by interfering with the host ADP-ribosylation signalling machinery and have been shown to be necessary for virus replication and pathogenesis.
• Viruses with these macrodomains include Chikungunya virus, MERS-CoV (camel flu) and SARS-CoV-2 (COVID-19).
• the aim of the present invention was to design a system that enables easy development of an assay suited for detection of a wide variety of ADP-ribosyl-binders and -hydrolases alike.
• the inventors reasoned that a non-hydro lysable ADP-ribose probe could be used to measure the binding of both hydrolysing- and non- hydro lysing ADP-ribose binders.
• Residues such as serine, aspartate or glutamate form an O-glycosidic bond and lysine, arginine or asparagine form an N-glycosidic bond with ADP-ribose. Additionally, a less common modification is the chemically stable linkage via an S-glycosidic bond that can be formed with cysteine residues. While many different ADP-ribosyl-hydrolases exist and can remove ADP-ribose from O- or N-glycosidic bonds, to date there is no enzyme in humans reported able to reverse the S- glycosidic linkage.
• Bordetella pertussis is known to efficiently catalyse the transfer of an ADP-ribose unit to a specific C-terminal cysteine residue in the cd subunits of heterotrimeric G proteins (God).
• God we reduced God to an 8-mer peptide and recombinantly fused it to the C-terminus of other proteins and still observed efficient modification, allowing site-specific addition of an ADP-ribose unit to any protein with accessible C-terminus.
• the present invention provides a method for detecting binding to an ADP-ribosyl group or a polymer thereof, wherein said group or polymer is coupled to a peptide or protein, the method comprising the steps of: i) providing a first entity comprising a first label or tag, said entity comprising an amino acid sequence comprising a cysteine residue whereto at least one ADP-ribosyl group or an analog thereof is coupled via an S-glycosidic bond; ii) contacting in an assay said first entity with a second entity, said second entity being or suspected of being capable of binding to an ADP-ribosyl group or polymer thereof coupled to a peptide or protein; and iii) measuring a signal derived from said first label or localized by said tag, wherein the signal detected is different or is localized differently when said second entity binds to said
• the present invention provides a kit for detecting binding to an ADP- ribosyl group or a polymer thereof, wherein said group or polymer is coupled to a peptide or protein, the kit comprising
• a first entity comprising a first label or tag, said entity comprising an amino acid sequence comprising a cysteine residue whereto at least one ADP-ribosyl group is coupled via an S-glycosidic bond, and
• a second entity coupled to a second label or tag, wherein said second entity is capable of binding to an ADP-ribosyl group or a polymer thereof coupled to a peptide or protein.
• the present invention provides a fusion protein comprising a first domain and a second domain, wherein said second domain comprises an amino acid sequence corresponding to the C-terminal sequence of a G alpha subunit of G proteins or having at least 75% sequence identity with the C-terminal sequence of a G alpha subunit of G proteins, preferably SEQ ID NO:4, and wherein said amino acid sequence comprises a cysteine residue whereto at least one ADP-ribosyl group or an analog thereof is coupled via an S-glycosidic bond.
• the present invention provides a system comprising i) a fusion protein comprising a first domain and a second domain, wherein said second domain comprises an amino acid sequence comprising a cysteine residue whereto at least one ADP-ribosyl group or an analog thereof is coupled via an S-glycosidic bond; and ii) a bio macromolecule preferably selected from a group consisting of macro domains, ARH family proteins, BRCT domains, PAR binding zinc motifs, and WE domains, wherein said bio macro molecule specifically recognizes said at least one ADP-ribosyl group or an analog thereof of said fusion protein; wherein, in said system, said bio macro molecule is bound to said at least one ADP-ribosyl group or an analog thereof of said fusion protein so that said bio molecule and said fusion protein are linked together and form a coupled entity.
• Figure 1 A molecular toolbox for in vitro interaction studies and assay development of ADP-ribosyl binding proteins,
• (a) Site-specific ADP-ribosylation of a C-terminal Gai-based 10-mer peptide (GAP tag) by pertussis toxin subunit SI (PtxSl) allows for generation of single S-glycosidically linked mono-ADP-ribosyl (MAR) groups
• MAR mono-ADP-ribosyl
• the MAR group of the GAP -tag can be extended to a poly- ADP-ribosyl (PAR) group by PARP2.
• This system can be used to measure binding of proteins interacting with mono- or poly- ADP-ribosyl groups by FRET or other binding technologies
• the GAP -tag can be used for site-specific labelling withNAD + analogs
• High-affinity ADP-ribosyl-binders fused to nanoluciferase (Niue) can be used as luminescent probes for fast, sensitive and selective detection of mono- and poly- ADP-ribosylated proteins in blot-based methods.
• Figure 2 Initial development of toolkit components, (a) Testing ADP-ribosylation by PtxSl with different Gai constructs. Unlabelled or YFP-fused full length Gai constructs and GAP -tagged YFP were tested as cysteine- ADPr acceptors when treated with 50 nM (+) or 250 nM (++) PtxSl. As controls, buffer or YFP-GAP in which the acceptor cysteine was mutated to alanine were used. Reactions were blotted on a nitrocellulose membrane and detection was done using Nluc-eAfl521. (b) The MAR group in the GAP -tag can be extended to PAR by PARP2.
• Gai-tag can be used to introduce site-specific modifications with NAD + analogs,
• GAP -tagged YFP was mixed with NAD + or 6-Biotin- 17-NAD + in absence or presence of PtxSl. The reactions were blotted on a nitrocellulose membrane and detection of biotin was done with Streptavidin-HRP.
• the resulting proteins YFP-GAP(MAR) or YFP-GAP(MAR-alkyne) or buffer were mixed with Cy3-azide or Cy5-azide and the copper(I)-catalyzed alkyne-azide cycloaddition reaction was performed by addition of 5 mM sodium ascorbate, 300 mM CuS0 4 and 600 mM L-Histidine.
• the samples were incubated for 3 hours at room temperature and blotted on nitrocellulose membranes and color images were taken. Unreacted Cy3-azide or Cy5-azide was removed by washing of the membranes in TBS-T and color images as well as fluorescent images were taken.
• Figure 4 Testing interactions of reported and potential readers and erasers with YFP- GAP.
• 250 nM CFP-fusion proteins were mixed with 500 nM YFP or with 500 nM YFP-GAP(PAR) in absence or presence of 100 mM ADP-ribose or 2.5 mM automodified PARP2.
• the ratiometric FRET signals were measured (d) Representative dose-response curve of 1 mM CFP-SARS- CoV nsp3 and 5 mM YFP-GAP(MAR) upon competition with ADP-ribose. (e) Representative dose-response curve of 250 nM CFP-ALC1 and 500 nM YFP-GAP(PAR) upon competition with PARylated PARP2.
• BRET Ratiometric BRET signal of Nluc-MD02 and YFP- Gcd(MAR) in absence (control) or presence of 200 mM ADP-ribose.
• the luminescence signal was detected upon excitation of donor beads (d) Measurement of interaction by bio layer interferometry. His-tagged YFP-GAP(MAR) was bound to the optical sensor surface and the change of signal after association (0 sec) or dissociation (120 sec) of unlabelled MD02 protein was determined in absence or presence of 3.16 mM ADP-ribose.
• Figure 6 Development of a screening assay based on the YFP-GAP(MAR) probe using CFP-tagged SARS-CoV-2 nsp3 macrodomain, (a) Signal validation for a screening assay with CFP-SARS-CoV-2. 1 mM SARS-CoV-2 was mixed with 5 mM YFP-GAP(MAR) in the absence or presence of 200 mM ADP-ribose and a Z’-factor of 0.7 was calculated (b) Screen of ENZO FDA-approved drug library.
• ADP-ribosylation including both “MARylation” and “PARylation” is catalyzed by an enzyme such as ADP-ribosyltransferases including poly(ADP-ribose)polymerase (PARPs), arginine-specific ecto-enzymes such as ARTCl-6 and a lot of bacterial toxins.
• ADP-ribosyltransferases include, in humans, PARPs, and in bacteria, a bacterial toxin DarT.
• MARylated means when ADP-ribosylation results in the transfer of a single mono(ADP- ribose) (MAR) group on a protein or nucleic acid.
• PARP ADP-ribosylation results in the transfer of multiple ADP-ribose (ADPr) group on a protein or nucleic acid.
• PARP family enzyme or ”PARP refers to poly (ADP-ribose) polymerases (PARPs) which are a family of related enzymes that share the ability to catalyze the transfer of ADP-ribose to target proteins.
• PARPs play an important role in various cellular processes, including modulation of chromatin structure, transcription, replication, recombination, and DNA repair.
• G alpha subunit or ”Gai refers herein to one of the three types of subunits (i.e. alpha (a), beta (b) and gamma (g) subunits) of G proteins, which are membrane-associated, heterotrimeric G proteins.
• G proteins also known as guanine nucleotide-binding proteins, are a family of proteins that act as molecular switches inside cells, and are involved in transmitting signals from a variety of stimuli outside a cell to its interior.
• SEQ ID NO:4 An example of human G alpha subunit sequence is shown in SEQ ID NO:4.
• polypeptide refers to a polymer of amino acid residues.
• the terms apply to amino acid polymers in which one or more amino acid residue is an analog or mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
• Polypeptides can be modified, e.g., by the addition of carbohydrate residues to form glycoproteins.
• polypeptide include glycoproteins, as well as non-glycoproteins.
• the term "signal" refers herein to any physical or chemical effect.
• the signal may be for example a luminous signal, for example a fluorescent, luminescent, colorimetric or electric, this list not being limiting.
• luminescent protein or ’’luminescent label refers to an entity or domain which has the property of releasing, in the form of photons with an energy of nonthermal origin, a part of the energy absorbed during an excitation. It therefore involves the deactivation of an excited molecule toward a lower energy state.
• a luminescent molecule is a molecule capable of acting on an appropriate substance in order to generate luminescence.
• the luminescent protein or label has the property of emitting blue, yellow or green light.
• the luminescent protein can be chosen from among those known to those skilled in the art.
• fluorescent label refers to a molecule having the property of absorbing the light energy (excitation light) and the restore rapidly in the form of fluorescent light, by emission of a photon in a very rapid manner (emission light). Once the energy of the photon absorbed, the molecule is then generally in a state electronically energized. In other words, it may be a fluorophore or a fluorochrome.
• FRET refers to fluorescent resonance energy transfer processes that occur between two chromophores.
• the chromophores as used herein comprise, for example, fluorescent, luminescent and other non-fluorescent components.
• BRET refers to Resonance Energy Transfer (RET) between a bio luminescent donor moiety (i.e. a BRET energy donor) and a fluorescent acceptor moiety (i.e. a BRET energy acceptor).
• RET Resonance Energy Transfer
• tag as used herein is meant to be understood in its broadest sense and to include, but is not limited to any suitable enzymatic, fluorescent, or radioactive labels and suitable epitopes, including but not limited to biotin tag, HA-tag, Myc-tag, T7, His-tag, FLAG-tag, Calmodulin binding proteins, glutathione- S -transferase, strep-tag, KT3-epitope, EEF- epitopes, green- fluorescent protein and variants thereof.
• a “tag” can also be any means to bind and/or immobilize a protein, such as the MARylated or PARylated protein of the present invention, to a surface.
• domain can be interpreted herein to encompass functional amino acid sequences in a polypeptide, such as sequences for binding or target sites for post-translational modifications, which retain their function when incorporated to a fusion protein.
• the present invention provides a system for in vitro studies that allows for simple and efficient setup of binding assays for ADP-ribosyl readers and erasers based on site-specific cysteine ADP- ribosylation. We extended this system and demonstrated the ability to modify proteins at a C- terminal peptide tag with chemically modified NAD + -analogs. This method open ways for the development of various in-vitro assay systems (Figure 1). To show the applicability for screening, we set up a binding assay for the macrodomain of SARS-CoV-2 non-structural protein 3 and identified the FDA approved drug suramin as moderate inhibitor.
• the present invention is directed to a method for detecting binding to an ADP- ribosyl group or a polymer thereof, wherein said group or polymer is coupled to a peptide or protein, the method comprising the steps of: i) providing a first entity comprising a first label or tag, said entity comprising an amino acid sequence comprising a cysteine residue whereto at least one ADP-ribosyl group or an analog thereof is coupled via an S-glycosidic bond; ii) contacting in an assay said first entity with a second entity, said second entity being or suspected of being capable of binding to an ADP-ribosyl group or polymer thereof coupled to a peptide or protein; and iii) measuring a signal derived from said first label or localized by said tag, wherein said assay is arranged so that the signal detected is different or is localized differently when said second entity binds to said at least one ADP-ribosyl group of the first entity from the signal detected when the method compris
• said amino acid sequence corresponds to the C-terminal sequence of a G alpha subunit of G proteins, preferably of SEQ ID NO:4, or has at least 75% sequence identity with the C-terminal sequence of said G alpha subunit and wherein, preferably, said amino acid sequence corresponding to the C-terminal sequence of said G alpha subunit or having at least 75% sequence identity with the C-terminal sequence of heterotrimeric G proteins is at least 4, and more preferably up to 50, 60, 70, 80, 90, 100, 150, 200, 250 or 300 amino acids long sequence or peptide.
• the coupling of said at least one ADP-ribosyl group to said cysteine residue via said S-glycosidic was catalyzed by a pertussis toxin and in case of a polymer preferably extended by a PARP family enzyme.
• said first entity comprises at least 4 amino acid long C- terminal sequence CGLF (SEQ ID NO:l) or CGLY (SEQ ID NO:2) corresponding to the C- terminal sequence of G alpha subunit of G proteins, and wherein at least one ADP-ribosyl group is coupled to the cysteine (C) of SEQ ID NO:l or SEQ ID NO:2 via a S-glycosidic bond.
• said first entity comprises C-terminal sequence KX 1 NLKX 2 CGLX 3 (SEQ ID NOG), wherein Xi is E or N, X is E or D, and X 3 is F or Y.
• said first entity is a fusion protein preferably comprising without limitation a luminescent or fluorescent protein domain or entity.
• said first entity is a fusion protein comprising without limitation a binding or enzymatic tag such as GST-tag or a digoxigenin tag.
• said second entity comprises a bio macro molecule capable of binding to said ADP-ribosyl group or a polymer thereof coupled to a peptide or protein.
• said biomacromolecule is selected without limitation from a group consisting of macro domains, ADP-ribosyl-acceptor hydrolase (ARH) family proteins, BRCA1 C-terminal (BRCT) domains, Poly(ADP-ribose)-binding zinc finger motifs, and a conserved globular WE domain of poly-ADP-ribose polymerase homo logs.
• ADP-ribosyl-acceptor hydrolase (ARH) family proteins BRCA1 C-terminal (BRCT) domains
• BRCT BRCA1 C-terminal domains
• Poly(ADP-ribose)-binding zinc finger motifs a conserved globular WE domain of poly-ADP-ribose polymerase homo logs.
• said second entity comprises a second label and in step iii) the signal(s) derived from the first and second labels is/are measured, wherein the signal(s) detected is/are different or differently localized when said second entity binds to said at least one ADP-ribosyl group of the first entity from the signal(s) detected when the binding interaction between said second entity and said ADP-ribosyl group has not occurred.
• said first and second labels are distinct luminescent or fluorescent labels.
• a candidate inhibitor compound is also added to the assay in step ii), wherein said candidate inhibitor is known or suspected to inhibit the binding interaction between said second entity and said ADP-ribosyl group or polymer thereof coupled to said first entity.
• said candidate inhibitor compound is found to be an inhibitor of the ADP-ribosyl binding if said binding interaction is inhibited in the assay in the presence of said candidate inhibitor but not in the absence of said candidate inhibitor.
• the method of the invention comprises the steps of: i) providing a first luminescent or fluorescent fusion protein comprising an amino acid sequence comprising a cysteine residue whereto at least one ADP-ribosyl group is coupled via an S-glycosidic bond; ii) contacting in an assay said first luminescent or fluorescent fusion protein with a second luminescent or fluorescent fusion protein capable of binding an ADP-ribosyl group and with a candidate inhibitor compound; and iii) measuring luminescence or fluorescence signals from said assay, wherein the signal detected is different when the second fusion protein binds to said at least one ADP-ribosyl group of the first fusion protein from the signal detected when the interaction between said second fusion protein and said ADP-ribosyl group is inhibited by the presence of said candidate inhibitor compound, wherein said candidate inhibitor compound is found to be an inhibitor of ADP-ribosyl binding if said binding interaction is inhibited in the assay
• said first and second fusion proteins comprise a fluorescent protein selected from a group consisting of: GFP ("Green Fluorescent Protein”), YFP ("Yellow Fluorescent Protein”), CFP (“Cyan Fluorescent Protein), eYFP (“Enhanced Yellow Fluorescent Protein”, eCFP (“Enhanced Cyan Fluorescent Protein”), derivatives and variants thereof, so that the fluorescent protein of the first fusion protein is preferably distinct from the fluorescent protein of the second fusion protein.
• GFP Green Fluorescent Protein
• YFP Yellow Fluorescent Protein
• CFP Cyan Fluorescent Protein
• eYFP Enhanced Yellow Fluorescent Protein
• eCFP Enhanced Cyan Fluorescent Protein
• the method of the invention comprises initial steps of:
• the present invention also provides a kit for detecting binding to an ADP-ribosyl group or a polymer thereof, wherein said group or polymer is coupled to a peptide or protein, the kit comprising
• a first entity comprising a first label or tag, said entity comprising an amino acid sequence comprising a cysteine residue whereto at least one ADP-ribosyl group is coupled via an S-glycosidic bond, and
• a second entity coupled to a second label or tag, wherein said second entity is capable of binding to an ADP-ribosyl group or a polymer thereof coupled to a peptide or protein.
• said amino acid sequence preferably corresponds to the C-terminal sequence of a G alpha subunit of G proteins, preferably of SEQ ID NO:4, or has at least 75% sequence identity with the C-terminal sequence of a G alpha subunit of G proteins and wherein, more preferably, said C-terminal sequence corresponding to the C-terminal sequence of a G alpha subunit of G proteins or having at least 75% sequence identity with the C-terminal sequence of a G alpha subunit of G proteins is at least 4, and more preferably up to 50, 60, 70, 80, 90, 100, 150, 200, 250 or 300 amino acids long sequence or peptide, most preferably of the C-terminal of SEQ ID NO:4 or a sequence having at least 75% sequence identity thereto.
• said first and second labels can be without limitation distinct luminescent or fluorescent labels.
• said first entity is a fusion protein comprising a binding or enzymatic tag such as GST-tag or a digoxigenin tag.
• said first and second entities are fusion proteins comprise without limitation a green fluorescent protein (GFP) or a derivative or variant thereof.
• GFP green fluorescent protein
• said first entity comprises at least 4 amino acid long amino acid sequence CGLF (SEQ ID NO:l) or CGFY (SEQ ID NO:2) corresponding to the C-terminal sequence of a G alpha subunit of G proteins, and wherein at least one ADP-ribosyl group is coupled to the cysteine (C) of SEQ ID NO:l or SEQ ID NO:2 via an S-glycosidic bond.
• CGLF SEQ ID NO:l
• CGFY SEQ ID NO:2
• said first entity comprises C-terminal sequence KX1NLKX2CGLX3 (SEQ ID NOG), wherein Xi is E or N, X is E or D, and X 3 is F or Y.
• said second entity comprises a bio macro molecule capable of binding to said ADP-ribosyl group or polymer thereof coupled to a peptide or protein.
• said bio macromolecule is selected without limitation from a group consisting of macro domains, ARH family proteins, BRCT domains, PAR binding zinc motifs, and WE domains.
• the present invention is also providing a fusion protein comprising a first domain and a second domain, wherein said second domain comprises an amino acid sequence corresponding to the C-terminal sequence of a G alpha subunit of G proteins, preferably of SEQ ID NO:4, or having at least 75% sequence identity with the C-terminal sequence of a G alpha subunit of G proteins, and wherein said amino acid sequence comprises a cysteine residue whereto at least one ADP-ribosyl group or an analog thereof is coupled via an S- glycosidic bond.
• said C-terminal sequence corresponds to the C -terminal sequence of a G alpha subunit of G proteins, preferably of SEQ ID NO:4 or has at least 75% sequence identity with the C-terminal sequence of a G alpha subunit of G proteins is at least 4 amino acids long sequence or peptide.
• said amino acid sequence of said second domain comprises amino acid sequence CGLF (SEQ ID NO:l) or CGLY (SEQ ID NO:2) corresponding to the C-terminal sequence of a G alpha subunit of G proteins, and wherein at least one ADP-ribosyl group is coupled to the cysteine (C) of SEQ ID NO:l or SEQ ID NO:2 via an S-glycosidic bond.
• said amino acid sequence of the second domain comprises C-terminal sequence KX1NLKX2CGLX3 (SEQ ID NOG), wherein Xi is E or N, X2 is E or D, and X3 is F or Y.
• said first domain is a fluorescent protein preferably selected from a group consisting of: GFP ("Green Fluorescent Protein”), YEP ("Yellow Fluorescent Protein”), CFP (“Cyan Fluorescent Protein), eYFP (“Enhanced Yellow Fluorescent Protein”, eCFP (“Enhanced Cyan Fluorescent Protein”), derivatives and variants thereof.
• GFP Green Fluorescent Protein
• YEP Yellow Fluorescent Protein
• CFP Cyan Fluorescent Protein
• eYFP Enhanced Yellow Fluorescent Protein
• eCFP Enhanced Cyan Fluorescent Protein
• the present invention is further directed to a system comprising i) a fusion protein comprising a first domain and a second domain, wherein said second domain comprises an amino acid sequence comprising a cysteine residue whereto at least one ADP-ribosyl group or an analog thereof is coupled via an S-glycosidic bond; and ii) a bio macromolecule preferably selected from a group consisting of macro domains, ARH family proteins, BRCT domains, PAR binding zinc motifs, and WE domains, wherein said bio macro molecule specifically recognizes said at least one ADP-ribosyl group or an analog thereof of said fusion protein; wherein, in said system, said bio macro molecule is bound to said at least one ADP-ribosyl group or an analog thereof of said fusion protein so that said bio molecule and said fusion protein are linked together and form a coupled entity.
• said second domain comprises an amino acid sequence corresponding to the C-terminal sequence of a G alpha subunit of G proteins, preferably of SEQ ID NO:4, or having at least 75% sequence identity with the C-terminal sequence of a G alpha subunit of G proteins.
• said system comprises means to detect the presence of said coupled entity in said system.
• Said means can preferably be selected from a group of luminescent and fluorescent labels and devices capable of receiving a signal from these labels.
• Expression constructs for CFP- or Nanoluciferase-fused proteins were cloned into pNIC28- CFP or pNH-Nluc by sequence and ligation independent cloning.
• Other protein constructs were cloned into pNIC28-Bsa or pNIC-MBP vectors.
• the plasmids were transformed to E. coli BL21(DE3) or E. coli Rosetta 2 cells.
• Terrific Broth (TB) autoinduction media including trace elements (Formedium, Hunstanton, Norfolk, England) was supplemented with 8 g/1 glycerol and antibiotics and inoculated with 1 : 100 of preculture grown over night in LB.
• the flasks were incubated shaking at 37 °C until an OD600 of about 1 was reached. The temperature was set to 18 °C and incubation continued overnight.
• the cells were collected by centrifugation at 4,200 x g for 30 min at 4 °C.
• the pellets were resuspended in lysis buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 15 mM imidazole). Resuspended cells were stored at - 20 °C until purification.
• YFP with C-terminal Gai-peptide tag was purified by IMAC and dialyzed against 20 mM HEPES pH 7.5, 350 mM NaCl.
• YFP-Gcd was diluted to 100 mM in 50 mM sodium phosphate buffer pH 7.0 and mixed with 1.5 mM catalytic SI domain of pertussis toxin and 150 mM sodium b-Nicotinamide adenine dinucleotide. The reaction was incubated for an hour at room temperature. To ensure completeness of the reaction, a second 150 mM were added to the reaction. Incubation was continued for 1 h at room temperature.
• the reaction mixture loaded to an IMAC column to remove pertussis toxin, hydrolysis products and unreacted NAD + .
• IMAC was carried out as described in the purification procedures above.
• the buffer was exchanged to 20mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP and the MARylated YFP- Gcri was subsequently concentrated to about 1 mM concentration using a Amicon Ultra- 15 Centrifugal Filter Unit (MWCO: lOkDa).
• MWCO Amicon Ultra- 15 Centrifugal Filter Unit
• PARylated YFP-Gcd for FRET experiments was prepared from MARylated YFP-Gcd. 10 mM of MARylated YFP-Gcd was incubated in the presence of 400 nM PARP2 (residues 90-583) and 1 mM NAD + in a buffer solution containing 50 mM Tris [pH 8.0] and 5 mM MgC12 for 2 h at room temperature. The reacted sample was then purified using IMAC as described above to remove PARP2.
• the sample buffer was exchanged to 30 mM HEPES [pH 7.5], 150 mM NaCl, 10% glycerol, 0.5 mM TCEP using an Amicon Ultra- 15 Centrifugal Filter Unit (MWCO: 10 kDa).
• the protein was aliquoted and flash frozen in liquid nitrogen and stored at -70 °C.
• MARylated YFP-Gcd was incubated with 200 nM Tankyrase 1 SAM-catalytic domain dimer, 1 and 10 mM NAD + in a buffer solution containing 10 mM BisTrisPropane [pH 7.0], 0.01% Triton X-100. The reaction has carried out for 16 h at room temperature.
• the membrane was rinsed with 15 ml TBS-T and incubated on a shaker with 15 ml TBS-T for 15 min. After a final rinsing with 15 ml TBS-T, the membrane was imaged using 500 m ⁇ of 1 : 1000 NanoGlo substrate (Promega) diluted in 10 mM sodium phosphate buffer pH 7.0.
• TNKS1 construct was mixed with 1 mM NAD + in 50 mM Bis-Tris-Propane pH 7.0, 0.01% Triton X-100, 0.5 mM TCEP.
• TNKS1 construct was mixed with 2 mM snake venom phosphodiesterase I.
• the blocking solution was discarded, and the membrane was incubated on a shaker for 1 hour with 15 ml of 1 :5000 Streptavidin-HRP in blocking buffer. After discarding the Streptavidin-HRP solution, the membrane was rinsed with 15 ml TBS-T and incubated on a shaker with 15 ml TBS-T for 15 min. After a final rinsing with 15 ml TBS-T, the membrane was imaged using ECF solution (BioRad).
• YFP-Gai(6-Parg-MAR) was prepared as described above for YFP-Gai using 6-Parg-NAD + instead of NAD + .
• reactions were prepared in 25 mM HEPES pH 7.5 by mixing 15 mM of YFP-Gai(6-PARG- MAR) or YFP-Gai(MAR) with 10 mM sodium ascorbate, 50 mM Cy3 -azide or Cy5 -azide and pre-mixed 300 mM CuS04 and 600 mM L-Histidine. Additionally, controls without protein were prepared.
• the reactions were let incubate for 3 hours at room temperature and afterwards blotted on a nitrocellulose membrane (5 m ⁇ per spot).
• the membrane was washed in 15 ml TBS-T for 30 min and imaged. Fluorescence imaging was done with an Azure 600 imaging system (Azure Biosystems) using Cy3 or Cy5 filter settings, respectively.
• the samples were excited at 410 nm and emission at 477 nm and 527 nm wavelengths were measured.
• the ratiometric FRET value (rFRET) was calculated by dividing the fluorescence intensity at 527 nmby the fluorescence intensity at 477 nm.
• the experiments were carried out in assay buffer (10 mM Bis-Tris-Propane pH 7.0, 3% (w/v) PEG20,000, 0.01%(v/v) Triton X-100 and 0.5 mM TCEP) in 10 m ⁇ volume per well unless stated otherwise.
• the reactions were performed in 384-well white OptiPlates (PerkinElmer). A reaction volume of 40 m ⁇ per well was used. 50 nM Nluc-MD02 were mixed with 1 mM MARylated YFP-Gcd. The reaction was started by addition of 1 :4000 NanoGlo substrate (Promega, catalogue number N1110). The reaction was incubated for 5 minutes and the emission was measured at wavelengths of 445-470 nm and 520-545 nm using Tecan Spak multimode plate reader with luminescence readout and a settle time of 10 ms and integration time of 100 ms.
• the ratiometric BRET value was calculated by dividing the luminescence intensity and 520-545 nm by the luminescence intensity at 445-470 nm.
• the experiments were carried out in assay buffer (10 mM Bis-Tris-Propane pH 7.0, 3% (w/v) PEG20,000, 0.01%(v/v) Triton X-100 and 0.5 mM TCEP).
• the reaction was performed in a 384 well flat-grey Alphaplate (PerkinElmer) in a total volume of 25 m ⁇ .
• the reaction consisted of 300 nM His-tagged Gai(MAR) mixed with 300nM Bio-MD02 in a buffer containing (25 mM HEPES pH 7.5, 100 mM NaCl, and 0.1 mg/ml BSA).
• the plate was sealed and incubated for 80 min at RT with constant shaking at 300 rpm. Finally, 5 pg/ml nickel chelate acceptor and streptavidin donor beads were added to the plates followed by additional 3 hrs incubation.
• the plate contained blank wells (assay buffer and AlphaScreen beads only), control 1 (Bio-MD02, His-Gcd) and control 2 (Bio-MD02, modified His-Gcd and ADPr). Luminescence was read using Tecan infinite M1000 Pro plate reader with AlphaScreen detection module.
• Bio layer interferometry (BLI) assays were carried out in Octet Red system (Forte Bio) in a buffer containing 10 mM BisTrisPropane [pH7.0], 150 mM NaCl, 1% BSA, 0.02% TritonX- 100 and at 30 °C and shaking at 1500 rpm. 10 pg/ml YFP-Gcd or MARylated YFP-Gcd was loaded on Ni 2+ -NTA coated sensors, followed by a wash step in buffer. Association to MD02 was measured by dipping the sensors in solution containing 0-2 mM MD02 for 120 s, while for the dissociation step the sensors were dipped in buffer for 120 s.
• YFP-Gai or MARylated YFP-Gai were loaded onto N ⁇ 2+-NTA coated sensors.
• sensors were dipped in 100 nM MD02 mixed with a half-log dilution series of ADPr (10 nM to 10 mM) for 120 s and then transferred to buffer for the dissociation step.
• the SARS-CoV-2 nsp3 macrodomain without tags was diluted to 5 mM in 10 mM HEPES pH 7.5, 25 mM NaCl, 0.5 mM TCEP buffer and mixed with 5x SYPRO Orange. Samples were prepared with 10 mM, 50 mM, 100 mM or 1 mM of suramin. Samples in presence or absence of 1 mM ADP-ribose were used as controls. Samples were transferred to 96-well qPCR plates. Measurement was performed in a BioRad Cl 000 CFX96 thermal cycler. Data points for melting curves were recorded in 1 min intervals from 20-95 °C, with the temperature increasing by 1 °C/min. The analysis of the data was done in GraphPad Prism 7 using a nonlinear regression analysis (Boltzmann sigmoid equation) of normalized data. EXAMPLE 1.
• cysteine-ADP-glycosylhydrolase activity was detected in human erythrocytes and mitochondria, no specific human enzymes have been identified to date that have the ability to hydrolyse the S-glycosidic bond of cysteine- ADP-ribose.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Organic Chemistry (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Biotechnology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Microbiology (AREA)
• Medicinal Chemistry (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Biophysics (AREA)
• Cell Biology (AREA)
• Pathology (AREA)
• General Physics & Mathematics (AREA)
• Food Science & Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Toxicology (AREA)
• Gastroenterology & Hepatology (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=81648183

Family Applications (1)

Country Status (4)

Cited By (1)

Family Cites Families (1)

• 2022
  • 2022-05-06 EP EP22723157.8A patent/EP4334720A1/en active Pending
  • 2022-05-06 JP JP2023568450A patent/JP2024519737A/ja active Pending
  • 2022-05-06 US US18/289,576 patent/US20240241113A1/en active Pending
  • 2022-05-06 WO PCT/FI2022/050305 patent/WO2022234194A1/en not_active Ceased

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events